Yesterday we had bad news about Niaspan: The NIH has stopped a study with Abbott Laboratories’ cholesterol fighter Niaspan 18 months early after results showed the drug failed to prevent heart attacks and even may have boosted stroke risk. And as Bloomberg notes, the results could heighten the debate over whether raising good cholesterol actually helps patients…. ….In [...]